Abstract

Aim. The research provides a comparative analysis of the possible anticonvulsant action of different cardiac glycosides, namely: digoxin, lanatoside C, strophanthin G and corglycone. In addition, it detrmines the leading medication among the abovementioned ones by dose-dependence of its anticonvulsant action. Material and Methods. The research was performed on 66 random-bred albino male mice. The anticonvulsant effect of cardiac glycosides was studied in a baseline model of pentylenetetrazole-induced seizures. The first series of experiment evaluated the effect of cardiac glycosides on the course of model seizures in comparable doses of approximately 1/10 LD50 for the corresponding drug: digoxin, lanatoside C and strophanthin G - at a dose of 0.8 mg/kg; corglycone - at a dose of 1 mg/kg. The second series of experiments used the drug-leader, which was digoxin, in a wide dose range from 0.2 to 1.6 mg/kg. Digoxin, strophanthin G and corglycone were administered subcutaneously for 15 minutes, lanatoside C - intragastrically for 30 minutes before the induction of experimental seizures. Convulsive agent - pentylenetetrazole in the form of an aqueous solution was administered to animals subcutaneously at a dose of 80 mg/kg. Results and Discussion. Digoxin at a dose of 0.8 mg/kg under conditions of pentylenetetrazole-induced seizures shows a pronounced anticonvulsant activity: it is the only one among the studied cardiac glycosides that probably reduces lethality. In addition, digoxin prolongs the latency period of the first attacks, and reduces the number of clonic-tonic paroxysms in 1 mouse. Moderate anticonvulsant properties of lanatoside C were found both by a statistically significant decrease in the number of clonic-tonic seizures in 1 mouse, and by a significant reduction in the duration of the convulsive period. Although strophanthin G is unlikely to affect lethality, it moderately reduces the severity of pentylenetetrazole-induced seizures in mice, as evidenced by a statistically significant prolongation of the latency period of the first seizures, as well as a decrease in the number of clonic-tonic seizures in 1 mouse and the duration of seizures. Prophylactic administration of corglycone only prolongs the latency period of seizures and significantly reduces the number of clonic-tonic seizures in 1 mouse. The results of the dose-dependence study of digoxin anticonvulsant action show a clear anticonvulsant potential of this cardiac glycoside in a wide range of doses - from 0.2 to 1.6 mg/kg - with a maximum effect at a dose of 0.8 mg/kg. Conclusions. It was found that cardiac glycosides have a different severity of anticonvulsant effect: the most powerful anticonvulsant effect is due to digoxin, lanatoside C and strophanthin G have moderate properties, and the least pronounced effect is characteristic to corglycone. In addition, it was determined that digoxin exhibits anticonvulsant properties in a wide range of doses, and has the most pronounced anticonvulsant effect at a dose of 0.8 mg/kg. The obtained results substantiate the expediency of further in-depth study of digoxin as an anticonvulsant medicine.

Highlights

  • Âñòóï Øèðîêà ðîçïîâñþäæåí3ñòü åï3ëåïñ3¿ ó ñâ3òîâ3é ïîïóëÿö3¿ ðàçîì 3ç âèñîêèì â3äñîòêîì ïàö3oíò3â, ðåçèñòåíòíèõ äî â3äîìèõ ïðîòèåï3ëåïòè÷íèõ çàñîá3â (ÏÅÇ) [1, 8], ñòèìóëþþòü ïîñò3éíèé ïîøóê íîâèõ ï3äõîä3â äî ë3êóâàííÿ ö3o¿ õâîðîáè

  • The research provides a comparative analysis of the possible anticonvulsant action of different cardiac glycosides, namely: digoxin, lanatoside C, strophanthin G and corglycone

  • The anticonvulsant effect of cardiac glycosides was studied in a baseline model of pentylenetetrazole-induced seizures

Read more

Summary

V.V. Tsyvunin1 ORCID

D.V. Shtrygol' 2 ORCID: 0000-0003-3112-4703 D.P. Kavraiskyi 3 ORCID: 0000-0002-1943-4656 1 National University of Pharmacy in Kharkiv, Ukraine 2 V.N. Karazin Kharkiv National University in Kharkiv, Ukraine 3 Bogomolets National Medical University in Kyiv, Ukraine. Ïðîâåñòè ïîð3âíÿëüíèé àíàë3ç ìîæëèâî¿ àíòèêîíâóëüñèâíî¿ ä3¿ ïðåïàðàò3â ð3çíèõ ñåðöåâèõë3êîçèä3â: äèãîêñèíó, ëàíàòîçèäó Ñ, ñòðîôàíòèíó G òà êîðãë3êîíó, à òàêîæ âèçíà÷èòè äîçîçàëåæí3ñòü ïðîòèñóäîìíî¿ ä3¿ ë3äåðà ç-ïîì3æ çàçíà÷åíèõ ïðåïàðàò3â. Äîñë3äæåííÿ ïðîâåäåíå íà 66 á3ëèõ ðàíäîìáðåäíèõ ìèøàõ ñàìöÿõ. Àíòèêîíâóëüñèâíó ä3þ ñåðöåâèõë3êîçèä3â âèâ÷àëè íà áàçîâ3é ìîäåë ñóäîì, ñïðè÷èíåíèõ ïåíòèëåíòåòðàçîëîì. Ó ïåðø3é ñåð3¿ åêñïåðèìåíò3â îö3íþâàëè âïëèâ ñåðöåâèõë3êîçèä3â íà ïåðåá3ã ìîäåëüíèõ ñóäîì ó ç3ñòàâëþâàíèõ äîçàõ, ùî ñêëàäàþòü ïðèáëèçíî 1/10 LD50 äëÿ â3äïîâ3äíîãî ïðåïàðàòó: äèãîêñèí, ëàíàòîçèä Ñ òà ñòðîôàíòèí

Hock FJ: Drug Discovery and Evaluation
Loscher W: The holy grail of epilepsy prevention
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call